drugset / Trial / NCT02003365

Study to Characterize the Local Duration of Exposure From FX006 in Patients With Osteoarthritis of the Knee

NCT02003365

Phase 2 Completed 50 enrolled Pacira Pharmaceuticals, Inc
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study was to characterize the local duration of exposure of TCA for 2 doses of FX006 relative to 40 mg of TCA IR in patients with OA of the knee.

Timeline

Start
2013-11
Primary completion
2014-04
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Tafamidis Unknown 10 mg Other
Subject Tafamidis Unknown 40 mg Other
Comparator Triamcinolone Acetonide Other / unclassified 40 mg Other

Indications